logo
ResearchBunny Logo
Hetero-bivalent nanobodies provide broad-spectrum protection against SARS-CoV-2 variants of concern including Omicron

Medicine and Health

Hetero-bivalent nanobodies provide broad-spectrum protection against SARS-CoV-2 variants of concern including Omicron

H. Ma, X. Zhang, et al.

This groundbreaking study reveals two hetero-bivalent nanobodies that effectively neutralize various SARS-CoV-2 variants, including Omicron. Researchers, including Huan Ma, Xinghai Zhang, and Peiyi Zheng, highlight the potential of aRBD-2-5-Fc for COVID-19 prevention and treatment, demonstrating significant protection in hamsters.

00:00
00:00
Playback language: English
Abstract
The emergence of SARS-CoV-2 variants with adaptive mutations necessitates the development of broad-spectrum antivirals. This study investigated two hetero-bivalent nanobodies (Nbs), aRBD-2-5 and aRBD-2-7, previously shown to neutralize wild-type SARS-CoV-2. Crystal structures revealed that aRBD-2 binds to conserved RBD residues, maintaining binding to various variants including Omicron. Fusion with aRBD-5 or aRBD-7 enhanced binding affinity. Both aRBD-2-5-Fc and aRBD-2-7-Fc potently neutralized multiple variants *in vitro*. aRBD-2-5-Fc demonstrated prophylactic and therapeutic protection against Omicron BA.1 in hamsters, suggesting its potential for COVID-19 prevention and treatment.
Publisher
Cell Research
Published On
Jul 29, 2022
Authors
Huan Ma, Xinghai Zhang, Peiyi Zheng, Peter H. Dube, Weihong Zeng, Shaohong Chen, Qingyu Cheng, Yunru Yang, Yan Wu, Junhui Zhou, Xiaowen Hu, Yan Xiang, Huajun Zhang, Sandra Chiu, Tengchuan Jin
Tags
SARS-CoV-2
nanobodies
neutralization
Omicron
COVID-19
therapeutic protection
broad-spectrum antivirals
Listen, Learn & Level Up
Over 10,000 hours of research content in 25+ fields, available in 12+ languages.
No more digging through PDFs, just hit play and absorb the world's latest research in your language, on your time.
listen to research audio papers with researchbunny